ATTRv V30M Medications: Pills, Shots, or IV Infusions?
At a Glance
ATTRv V30M amyloidosis medications are administered in three main ways: daily oral pills (Tafamidis), subcutaneous injections given weekly to every three months (Eplontersen, Inotersen, Vutrisiran), and intravenous (IV) infusions given every three weeks (Patisiran).
In this answer
4 sections
For patients with ATTRv V30M amyloidosis, treatments are available as daily pills, subcutaneous injections (shots under the skin), or intravenous (IV) infusions [1][2]. The exact method and frequency of your treatment will depend on which medication you and your doctor choose [3].
Currently, there are two main classes of FDA-approved therapies for ATTRv amyloidosis: TTR stabilizers and TTR silencers [4]. Knowing how these medications are given—and how much time they require—can help you plan your life, work schedule, and travel around your treatment.
TTR Stabilizers
TTR stabilizers work by binding to the transthyretin (TTR) protein, preventing it from breaking apart and forming the harmful amyloid deposits that cause symptoms.
- Tafamidis (Vyndaqel/Vyndamax): This medication is taken as an oral pill [5]. It is swallowed once daily [6]. Because it is a pill you take at home, it generally causes the least disruption to daily life compared to treatments that require clinical visits or injections [7]. Monitoring mostly involves routine clinical follow-ups.
TTR Silencers
TTR silencers (also known as gene silencers) work by targeting the genetic instructions that create the TTR protein, significantly reducing the amount of TTR your liver produces [3]. These medications are administered either through injections or IV infusions.
Subcutaneous Injections (Shots)
Subcutaneous injections are delivered into the fatty tissue just under the skin, usually in the stomach, thigh, or back of the upper arm.
- Eplontersen (Wainua): Approved in late 2023, this medication is given as a once-monthly subcutaneous injection [8]. It comes in a single-dose auto-injector pen, making it easier for patients to administer at home [8]. Storage note: It is kept in the refrigerator but should sit at room temperature for about 30 minutes before use.
- Inotersen (Tegsedi): This medication is administered as a once-weekly subcutaneous injection using a prefilled syringe [1]. Patients are usually trained to self-administer these shots at home [7]. Note that this medication requires strict, regular blood and urine testing to monitor your platelet counts and kidney function [9].
- Vutrisiran (Amvuttra): This medication is administered once every 3 months [10]. Because of the longer time between doses, it must be given by a healthcare professional at a clinic or via a home health nurse [2].
Intravenous (IV) Infusions
IV infusions deliver medication directly into a vein.
- Patisiran (Onpattro): This treatment is administered as an intravenous (IV) infusion [11]. It is given once every 3 weeks [12]. You will need to receive it at an infusion center, a clinic, or via home health services. The infusion itself takes about 80 minutes [13]. You must also take premedications (such as antihistamines and corticosteroids) at least 60 minutes before the infusion starts to prevent allergic reactions [14]. Because these premedications can cause drowsiness, you may need someone else to drive you home.
Treatment Comparison Table
| Medication | Class | Delivery Method | Frequency | Setting |
|---|---|---|---|---|
| Tafamidis | Stabilizer | Oral Pill | Once Daily | At Home |
| Eplontersen | Silencer | Subcutaneous (Auto-injector) | Once Monthly | At Home |
| Inotersen | Silencer | Subcutaneous (Prefilled syringe) | Once Weekly | At Home |
| Vutrisiran | Silencer | Subcutaneous (Injection) | Every 3 Months | Clinic / Home Nurse |
| Patisiran | Silencer | IV Infusion | Every 3 Weeks | Clinic / Home Nurse |
Choosing the Right Option for Your Lifestyle
Each treatment method requires different levels of commitment. Daily pills and self-injections offer the convenience of staying at home but require you to remember your medication regularly. Infusions and three-month injections require visits with a healthcare professional but leave you free from daily or weekly treatment routines.
When discussing these options with your doctor, you should weigh how the administration route fits into your daily routine, travel plans, and comfort level with needles, medical visits, and required safety monitoring.
Common questions in this guide
How is Tafamidis taken for ATTRv amyloidosis?
Can I administer TTR silencer injections at home?
What should I expect during a Patisiran IV infusion?
Do ATTRv amyloidosis treatments require regular blood tests?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my specific ATTRv V30M symptoms, am I a better candidate for a daily pill, a self-injection, or an IV infusion?
- 2.If I choose a medication that requires shots or IV infusions, can those be administered by a home health nurse, or will I need to travel to a clinic?
- 3.What are the required monitoring tests for each of these options, and how often will I need to have my blood or urine tested?
- 4.If I choose an IV infusion like Patisiran, what exact premedications will I need to take, and will I be safe to drive myself home?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (14)
- 1
Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis.
Gales L
Pharmaceuticals (Basel, Switzerland) 2019; (12(2)) doi:10.3390/ph12020078.
PMID: 31117178 - 2
Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.
Nie T, Heo YA, Shirley M
Drugs 2023; (83(15)):1425-1432 doi:10.1007/s40265-023-01943-z.
PMID: 37728865 - 3
A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
Benbrahim M, Norman K, Sanchorawala V, et al.
Journal of cardiovascular pharmacology 2021; (77(5)):544-548 doi:10.1097/FJC.0000000000001004.
PMID: 33657048 - 4
Hereditary Transthyretin Amyloidosis and the Impact of Classic and New Treatments on Kidney Function: A Review.
Meléndrez-Balcázar E, Aranda-Vela K, Cervantes-Hernández A, López-Cureño S
American journal of kidney diseases : the official journal of the National Kidney Foundation 2024; (84(2)):224-231 doi:10.1053/j.ajkd.2024.01.527.
PMID: 38484868 - 5
Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story.
Burton A, Castaño A, Bruno M, et al.
Drug design, development and therapy 2021; (15()):1225-1243 doi:10.2147/DDDT.S289772.
PMID: 33776421 - 6
Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy.
Rettl R, Duca F, Binder C, et al.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2023; (30(1)):127-137 doi:10.1080/13506129.2022.2131385.
PMID: 36251806 - 7
Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain.
Galan L, Gonzalez-Moreno J, Martínez-Sesmero JM, et al.
Expert review of pharmacoeconomics & outcomes research 2021; (21(5)):967-973 doi:10.1080/14737167.2021.1900738.
PMID: 33724140 - 8
Eplontersen: First Approval.
Nie T
Drugs 2024; (84(4)):473-478 doi:10.1007/s40265-024-02008-5.
PMID: 38413492 - 9
A case of severe increase of liver enzymes in a ATTRv patient after one year of inotersen treatment.
Severi D, Palumbo G, Spina E, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2023; (44(4)):1419-1422 doi:10.1007/s10072-022-06568-w.
PMID: 36576645 - 10
Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy.
Planté-Bordeneuve V, Perrain V
Expert opinion on drug discovery 2024; (19(4)):393-402 doi:10.1080/17460441.2024.2306843.
PMID: 38281068 - 11
Advances in the treatment of hereditary transthyretin amyloidosis: A review.
Gertz MA, Mauermann ML, Grogan M, Coelho T
Brain and behavior 2019; (9(9)):e01371 doi:10.1002/brb3.1371.
PMID: 31368669 - 12
Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.
Conceição I
Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2019; (29(Suppl 1)):11-17 doi:10.1007/s10286-019-00626-8.
PMID: 31399774 - 13
Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis.
Yang J
Expert review of clinical pharmacology 2019; (12(2)):95-99 doi:10.1080/17512433.2019.1567326.
PMID: 30644768 - 14
[Current approaches for treatment of hereditary transthyretin amyloidosis (ATTR)].
Zibert A, Hüsing-Kabar A, Schmidt H
Deutsche medizinische Wochenschrift (1946) 2019; (144(20)):1438-1443 doi:10.1055/a-0848-9610.
PMID: 31594020
This page explains administration routes for ATTRv V30M amyloidosis medications for educational purposes only. Always consult your doctor to determine which treatment and administration method fits your medical needs and lifestyle.
Get notified when new evidence is published on ATTRV30M amyloidosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.